BR9711573A - Pepetìdeos c da insulina. - Google Patents
Pepetìdeos c da insulina.Info
- Publication number
- BR9711573A BR9711573A BR9711573-8A BR9711573A BR9711573A BR 9711573 A BR9711573 A BR 9711573A BR 9711573 A BR9711573 A BR 9711573A BR 9711573 A BR9711573 A BR 9711573A
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- peptide
- fragment
- insulin
- atpase
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 4
- 108091006112 ATPases Proteins 0.000 abstract 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 3
- 208000002249 Diabetes Complications Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 108010075254 C-Peptide Proteins 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003592 biomimetic effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 108010038088 glutamyl-glycyl-seryl-leucyl-glutamine Proteins 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 210000005233 tubule cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Patente de Invenção: <B>"PEPTìDIOS C DA INSULINA".<D> A presente invenção refere-se a um peptídio sendo um fragmento do peptídio C da insulina humana, o referido peptídio compreendendo a seq³ência ELGGGPGAG ou um fragmento da mesma, ou a seq³ência EGSLQ ou um fragmento da mesma, e tendo a capacidade de estimular a atividade da Na^ +^k^ +^ATPase. Também são proporcionados compostos orgânicos biomiméticos que exibem uma ativação da Na^ +^K^ +^ATPase e/ou ligação celular às células do túbulo renal e aos fibroblastos em pelo menos o nível exibido pelos peptídios acima mencionados ou os fragmentos dos mesmos. Esses peptídios e compostos têm utilidade no combate ao diabetes e as complicações diabéticas, ou para a estimulação da atividade da Na^+^K^+^ATPases
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9603533A SE520392C2 (sv) | 1996-09-27 | 1996-09-27 | Specifika peptider för behandling av diabetes mellitus |
PCT/GB1997/002627 WO1998013384A1 (en) | 1996-09-27 | 1997-09-26 | Insulin c-peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9711573A true BR9711573A (pt) | 2000-01-18 |
Family
ID=20404052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9711573-8A BR9711573A (pt) | 1996-09-27 | 1997-09-26 | Pepetìdeos c da insulina. |
Country Status (24)
Country | Link |
---|---|
US (1) | US6610649B2 (pt) |
EP (1) | EP0938503B1 (pt) |
JP (1) | JP2001500893A (pt) |
KR (1) | KR20000048643A (pt) |
AT (1) | ATE347562T1 (pt) |
AU (1) | AU741901B2 (pt) |
BG (1) | BG103362A (pt) |
BR (1) | BR9711573A (pt) |
CA (1) | CA2266416C (pt) |
CZ (1) | CZ108599A3 (pt) |
DE (1) | DE69737065T2 (pt) |
DK (1) | DK0938503T3 (pt) |
ES (1) | ES2278394T3 (pt) |
HU (1) | HUP0000432A3 (pt) |
IL (1) | IL129143A0 (pt) |
IS (1) | IS5008A (pt) |
NO (1) | NO991483L (pt) |
NZ (1) | NZ335231A (pt) |
PL (1) | PL332494A1 (pt) |
RU (1) | RU2206336C2 (pt) |
SE (1) | SE520392C2 (pt) |
SK (1) | SK39499A3 (pt) |
TR (1) | TR199900694T2 (pt) |
WO (1) | WO1998013384A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0022342D0 (en) | 2000-09-12 | 2000-10-25 | Creative Peptides Sweden Ab | Reduction of the electrocardiographic QT interval |
DE10055857A1 (de) * | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
AU2004204727B8 (en) * | 2003-01-06 | 2006-11-09 | Emisphere Technologies, Inc. | Night-time oral insulin therapy |
US20050026826A1 (en) * | 2003-01-17 | 2005-02-03 | Margarethe Hoenig | Feline proinsulin, insulin and constituent peptides |
US20050203001A1 (en) * | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
GB0323979D0 (en) | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
WO2005117937A2 (en) * | 2004-05-27 | 2005-12-15 | Essential Skincare Llc | Alpha-1- acid glycoprotein for the treatment of diabetes |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
GB0601950D0 (en) * | 2006-01-31 | 2006-03-15 | Creative Peptides Sweden Ab | Compositions and methods of treating diabetes |
EP2054437A2 (en) * | 2006-08-07 | 2009-05-06 | Teva Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
WO2009046847A2 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of peptide ll-37 as a therapeutic agent |
GB0723250D0 (en) * | 2007-11-28 | 2008-01-09 | Univ Leeds | Compositions and methods for reducing macrovascular complications in diabetic patients |
WO2010033207A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
US8410049B2 (en) * | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
NZ603399A (en) | 2010-05-17 | 2014-09-26 | Cebix Inc | Pegylated c-peptide |
EP2683393B1 (en) | 2011-02-11 | 2018-04-11 | The Regents of The University of Michigan | Tripeptide compositions and their use for treatment of diabetes |
EP2780030A4 (en) | 2011-11-17 | 2015-11-18 | Cebix Ab | PEGYLATED C-PEPTIDE |
RU2522897C1 (ru) * | 2013-04-16 | 2014-07-20 | Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" | Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты) |
KR101676542B1 (ko) * | 2014-12-30 | 2016-11-16 | 건국대학교 산학협력단 | 프로인슐린의 면역학적 용도 |
CN104888201B (zh) * | 2015-06-29 | 2018-04-27 | 齐锦生 | 用于防治糖尿病及其慢性并发症的肽类药物 |
SG11201906939XA (en) | 2017-02-06 | 2019-08-27 | Resiliun B V | Interaction between c-peptides and elastin receptor, a model for understanding vascular disease |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU166913B (pt) * | 1972-05-15 | 1975-06-28 | ||
JPS5210872B2 (pt) | 1973-07-14 | 1977-03-26 | ||
JPS55105653A (en) * | 1978-10-02 | 1980-08-13 | Shionogi & Co Ltd | Tyrosyl c-peptides |
IL66611A0 (en) | 1981-08-27 | 1982-12-31 | Lilly Co Eli | Pharmaceutical formulations comprising human insulin and human c-peptide |
DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
US4581165A (en) * | 1984-06-14 | 1986-04-08 | Eli Lilly And Company | Anti-diabetic compounds |
US5104854A (en) | 1989-02-01 | 1992-04-14 | Washington University | Antiviral peptides |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
US5364757A (en) | 1990-05-21 | 1994-11-15 | Administrators Of The Tulane Educational Fund | Methods of supporting a diagnosis of systemic lupus erythematosus |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
JPH05268982A (ja) | 1992-03-27 | 1993-10-19 | Hoechst Japan Ltd | 骨形成作用を有する新規な蛋白質およびその製造法 |
DK0640101T3 (da) | 1992-04-13 | 2000-05-15 | Oklahoma Med Res Found | Fremgangsmåder og reagenser til diagnosticering af autoantistoffer |
WO1994025071A1 (en) | 1993-05-05 | 1994-11-10 | Keith Rose | Polyoxime compounds and their preparation |
AT400723B (de) | 1993-08-27 | 1996-03-25 | Biomay Prod & Handel | Rekombinante alternaria alternata allergene |
ES2130629T3 (es) | 1994-07-08 | 1999-07-01 | Dartmouth College | Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i. |
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
GB9422175D0 (en) | 1994-11-03 | 1994-12-21 | Univ Dundee | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
CA2249742A1 (en) | 1996-03-15 | 1997-09-18 | Steven G. Reed | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
US6150500A (en) | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
-
1996
- 1996-09-27 SE SE9603533A patent/SE520392C2/sv not_active IP Right Cessation
-
1997
- 1997-09-26 TR TR1999/00694T patent/TR199900694T2/xx unknown
- 1997-09-26 JP JP10515410A patent/JP2001500893A/ja not_active Ceased
- 1997-09-26 CZ CZ991085A patent/CZ108599A3/cs unknown
- 1997-09-26 HU HU0000432A patent/HUP0000432A3/hu unknown
- 1997-09-26 NZ NZ335231A patent/NZ335231A/xx unknown
- 1997-09-26 DK DK97942119T patent/DK0938503T3/da active
- 1997-09-26 AT AT97942119T patent/ATE347562T1/de not_active IP Right Cessation
- 1997-09-26 ES ES97942119T patent/ES2278394T3/es not_active Expired - Lifetime
- 1997-09-26 EP EP97942119A patent/EP0938503B1/en not_active Expired - Lifetime
- 1997-09-26 IL IL12914397A patent/IL129143A0/xx unknown
- 1997-09-26 WO PCT/GB1997/002627 patent/WO1998013384A1/en active IP Right Grant
- 1997-09-26 US US09/269,439 patent/US6610649B2/en not_active Expired - Fee Related
- 1997-09-26 DE DE69737065T patent/DE69737065T2/de not_active Expired - Lifetime
- 1997-09-26 RU RU99108434/14A patent/RU2206336C2/ru not_active IP Right Cessation
- 1997-09-26 CA CA002266416A patent/CA2266416C/en not_active Expired - Fee Related
- 1997-09-26 AU AU43915/97A patent/AU741901B2/en not_active Ceased
- 1997-09-26 PL PL97332494A patent/PL332494A1/xx unknown
- 1997-09-26 BR BR9711573-8A patent/BR9711573A/pt not_active Application Discontinuation
- 1997-09-26 KR KR1019990702585A patent/KR20000048643A/ko not_active Application Discontinuation
- 1997-09-26 SK SK394-99A patent/SK39499A3/sk unknown
-
1999
- 1999-03-23 IS IS5008A patent/IS5008A/is unknown
- 1999-03-26 NO NO991483A patent/NO991483L/no not_active Application Discontinuation
- 1999-04-27 BG BG103362A patent/BG103362A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BG103362A (en) | 2000-05-31 |
IL129143A0 (en) | 2000-02-17 |
ATE347562T1 (de) | 2006-12-15 |
PL332494A1 (en) | 1999-09-13 |
HUP0000432A3 (en) | 2000-10-30 |
SE520392C2 (sv) | 2003-07-01 |
IS5008A (is) | 1999-03-23 |
DE69737065T2 (de) | 2007-06-28 |
SK39499A3 (en) | 1999-10-08 |
US20020107175A1 (en) | 2002-08-08 |
ES2278394T3 (es) | 2007-08-01 |
NO991483L (no) | 1999-05-18 |
WO1998013384A1 (en) | 1998-04-02 |
RU2206336C2 (ru) | 2003-06-20 |
AU741901B2 (en) | 2001-12-13 |
JP2001500893A (ja) | 2001-01-23 |
EP0938503A1 (en) | 1999-09-01 |
DK0938503T3 (da) | 2007-04-10 |
NZ335231A (en) | 2000-11-24 |
SE9603533D0 (sv) | 1996-09-27 |
TR199900694T2 (xx) | 1999-06-21 |
CZ108599A3 (cs) | 1999-08-11 |
NO991483D0 (no) | 1999-03-26 |
SE9603533L (sv) | 1998-03-28 |
CA2266416C (en) | 2008-04-29 |
DE69737065D1 (en) | 2007-01-18 |
AU4391597A (en) | 1998-04-17 |
KR20000048643A (ko) | 2000-07-25 |
US6610649B2 (en) | 2003-08-26 |
EP0938503B1 (en) | 2006-12-06 |
CA2266416A1 (en) | 1998-04-02 |
HUP0000432A2 (hu) | 2000-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9711573A (pt) | Pepetìdeos c da insulina. | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
BR9810378A (pt) | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero | |
DE69025943D1 (de) | Verwendung von Spiperone-derivate zur Immunosuppression | |
Lonsdale-Eccles et al. | A phosphorylated keratohyalin-derived precursor of epidermal stratum corneum basic protein. | |
PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
DE3772521D1 (de) | Insulinzubereitung fuer nicht-parenterale verabreichung. | |
BR9710452A (pt) | Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos | |
SE8204064L (sv) | Vevnadslim samt sett for dess framstellning | |
DK0692970T3 (da) | Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli | |
ES2121479T3 (es) | Solucion estabilizadora para proteinas y peptidos. | |
BRPI0408229A (pt) | preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação | |
BR9713884A (pt) | Benzamida heterociclicamente substituìda, usos da mesma e de cetobenzamidoaldeìdos desta, e, preparação medicamentosa. | |
DK278088A (da) | Insulinblandindgsktystaller, deres fremstilling og anvendelse | |
EA199700241A1 (ru) | Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран | |
DE69133077T2 (de) | Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung | |
BR9915436A (pt) | Certas caprolactamas substituìdas, composições farmacêuticas contendo as mesmas e seu uso no tratamento de tumores | |
DE68910973T2 (de) | Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden. | |
DE69736158D1 (de) | Glutamine: Fructose-6-Phosphat Amidotransferase (GFAT), ihre Herstellung und Verwendung | |
BR9713087A (pt) | Composição farmacêutica estabilizada, utilização e processo para preparar a mesma, e, utilização de ácido metanossulfÈnico ou ácido clorìdrico | |
BR9811422A (pt) | Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular | |
BR9916811A (pt) | Acil-tripeptìdeos heterocìclicos substituìdos úteis como moduladores receptores de trombina | |
BR9813037A (pt) | Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa | |
ES2185922T3 (es) | Composiciones para el tratamiento de quemaduras y ulceras externas y procedimiento para la preparacion de las mismas. | |
BR0012274A (pt) | Dna codificante para beta-tubulina e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB34 | Technical and formal requirements: requirement - article 34 of industrial property law | ||
FA14 | Dismissal: dismissal - article 34 of industrial property law | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |